Blaine Eldred

DownloadHi-Res Photo

About

Biography

Blaine Eldred is an aspiring physician-scientist dedicated to the study and treatment of brain cancer. He graduated from UCLA in 2019 with a degree in neuroscience and a minor in biomedical research, where he developed a strong interest in cancer biology and translational medicine. After graduation, he was hired by Dr. Albert Lai as a laboratory manager and contributed to a variety of interdisciplinary research projects until 2025. Blaine’s long-term goal is to become an academic physician-scientist focused on advancing the understanding of brain tumors and developing more effective treatments for patients.

Last Updated on June 25, 2025.

Education & Training

BS: UCLA, Neuroscience (2019)

- Download CV

Research

Overview

Blaine Eldred is a physician-scientist trainee specializing in neuro-oncology and translational cancer research. At UCLA, Blaine contributed to numerous interdisciplinary projects that leveraged imaging, pathology, and molecular profiling to better understand tumor biology and therapeutic response in diffuse gliomas.

ORCID
0000-0002-3351-3895

Research at a Glance

Publications Timeline

A big-picture view of Blaine Eldred's research output by year.

12Publications

Publications

Featured Publications

D-2-HG Inhibits IDH1mut Glioma Growth via FTO Inhibition and Resultant m6A Hypermethylation.
Pianka ST, Li T, Prins TJ, Eldred BSC, Kevan BM, Liang H, Zapanta Rinonos S, Kornblum HI, Nathanson DA, Pellegrini M, Liau LM, Nghiemphu PL, Cloughesy TF, Lai A. D-2-HG Inhibits IDH1mut Glioma Growth via FTO Inhibition and Resultant m6A Hypermethylation. Cancer Res Commun 2024, 4: 876-894. PMID: 38445960, DOI: 10.1158/2767-9764.CRC-23-0271.
Peer-Reviewed Original Research
dCas9/CRISPR-based methylation of O-6-methylguanine-DNA methyltransferase enhances chemosensitivity to temozolomide in malignant glioma.
Zapanta Rinonos S, Li T, Pianka ST, Prins TJ, Eldred BSC, Kevan BM, Liau LM, Nghiemphu PL, Cloughesy TF, Lai A. dCas9/CRISPR-based methylation of O-6-methylguanine-DNA methyltransferase enhances chemosensitivity to temozolomide in malignant glioma. J Neurooncol 2024, 166: 129-142. PMID: 38224404, DOI: 10.1007/s11060-023-04531-z.
Peer-Reviewed Original Research
Prognostic value of O (6)-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas.
Lam K, Eldred BSC, Kevan B, Pianka S, Eldred BA, Zapanta Rinonos S, Yong WH, Liau LM, Nghiemphu PL, Cloughesy TF, Green RM, Lai A. Prognostic value of O (6)-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas. Neurooncol Adv 2022, 4: vdac030. PMID: 35386566, DOI: 10.1093/noajnl/vdac030.
Peer-Reviewed Original Research
Targeted next-generation sequencing of 565 neuro-oncology patients at UCLA: A single-institution experience.
Ji MS, Eldred BSC, Liu R, Pianka ST, Molaie D, Kevan B, Pan S, Lai TJ, Nguyen NT, Chow FE, Yong WH, Cox CD, Reeh DN, Li T, Liau LM, Nghiemphu PL, Cloughesy TF, Li G, Lai A. Targeted next-generation sequencing of 565 neuro-oncology patients at UCLA: A single-institution experience. Neurooncol Adv 2020, 2: vdaa009. PMID: 32118206, DOI: 10.1093/noajnl/vdaa009.
Peer-Reviewed Original Research

2025

Advanced imaging characterization of post-chemoradiation glioblastoma stratified by diffusion MRI phenotypes known to predict favorable anti-VEGF response.
Sanvito F, Kryukov I, Yao J, Teraishi A, Raymond C, Gao J, Miller C, Nghiemphu PL, Lai A, Liau LM, Patel K, Everson RG, Eldred BSC, Prins RM, Nathanson DA, Salamon N, Cloughesy TF, Ellingson BM. Advanced imaging characterization of post-chemoradiation glioblastoma stratified by diffusion MRI phenotypes known to predict favorable anti-VEGF response. J Neurooncol 2025, 173: 583-594. PMID: 40227555, DOI: 10.1007/s11060-025-05019-8.
Peer-Reviewed Original Research

2024

Radio-pathomic estimates of cellular growth kinetics predict survival in recurrent glioblastoma.
Oshima S, Yao J, Bobholz S, Nagaraj R, Raymond C, Teraishi A, Guenther AM, Kim A, Sanvito F, Cho NS, Eldred BSC, Connelly JM, Nghiemphu PL, Lai A, Salamon N, Cloughesy TF, LaViolette PS, Ellingson BM. Radio-pathomic estimates of cellular growth kinetics predict survival in recurrent glioblastoma. CNS Oncol 2024, 13: 2415285. PMID: 39535237, DOI: 10.1080/20450907.2024.2415285.
Peer-Reviewed Original Research

2023

Change in volumetric tumor growth rate after cytotoxic therapy is predictive of overall survival in recurrent glioblastoma.
Oshima S, Hagiwara A, Raymond C, Wang C, Cho NS, Lu J, Eldred BSC, Nghiemphu PL, Lai A, Telesca D, Salamon N, Cloughesy TF, Ellingson BM. Change in volumetric tumor growth rate after cytotoxic therapy is predictive of overall survival in recurrent glioblastoma. Neurooncol Adv 2023, 5: vdad084. PMID: 37554221, DOI: 10.1093/noajnl/vdad084.
Peer-Reviewed Original Research
A single-institution retrospective analysis of pathologically determined malignant transformation in IDH mutant glioma patients.
Liu V, Wetzel EA, Eldred BSC, Zapanta Rinonos S, Prins TJ, Khanlou N, Liau LM, Chong R, Nghiemphu PL, Cloughesy TF, Ellingson BM, Lai A. A single-institution retrospective analysis of pathologically determined malignant transformation in IDH mutant glioma patients. Neurooncol Adv 2023, 5: vdad036. PMID: 37152809, DOI: 10.1093/noajnl/vdad036.
Peer-Reviewed Original Research
Retrospective examination of pseudoprogression in IDH mutant gliomas.
Wetzel EA, Farrell MJ, Eldred BSC, Liu V, Saha I, Zapanta Rinonos S, Prins T, Li T, Cao M, Hegde J, Kaprealian T, Khanlou N, Liau LM, Nghiemphu PL, Cloughesy TF, Chong RA, Ellingson BM, Lai A. Retrospective examination of pseudoprogression in IDH mutant gliomas. Neurooncol Adv 2023, 5: vdad028. PMID: 37128507, DOI: 10.1093/noajnl/vdad028.
Peer-Reviewed Original Research
Determining venous thromboembolism risk in patients with adult-type diffuse glioma.
Burdett KB, Unruh D, Drumm M, Steffens A, Lamano J, Judkins J, Schwartz M, Javier R, Amidei C, Lipp ES, Peters KB, Lai A, Eldred BSC, Heimberger AB, McCortney K, Scholtens DM, Horbinski C. Determining venous thromboembolism risk in patients with adult-type diffuse glioma. Blood 2023, 141: 1322-1336. PMID: 36399711, DOI: 10.1182/blood.2022017858.
Peer-Reviewed Original Research

See All Publications